Spectrum Pharma

ROLVEDON

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Spectrum Pharma

Rolvedon HCPCS:

J1449

HCPCS Code Descriptor:

Injection, eflapegrastim-xnst, 0.1 mg

Category:

J Code

Rolvedon NDCs:

76961-0101-01

Primary Type:

Oncology Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Rolvedon CPT Codes:

Potential CPT administration codes for Rolvedon can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Rolvedon:

ROLVEDON is an Oncology Colony Stimulating Factor drug manufactured by Spectrum Pharma and administered via the Subcutaneous route of administration. The J Code: J1449 is aligned to the drug ROLVEDON.

ACCESS PRICING AND MORE BY REGISTERING

J1449 Added Date:

April 1, 2023

J1449 Effective Date:

April 1, 2023

J1449 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Rolvedon billing and coding information.
Rolvedon patient assistance information can be found through ACCESS4ME at the URL: https://www.access4me.com/patient-support/
ROLVEDON prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for ROLVEDON. Please check back in a few weeks.